Pelthos Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PTHS | HYL.BR | FBIO | IBO | CTXR | PHAT | |
|---|---|---|---|---|---|---|
| Market cap | 39.91M | 99.68M | 65.70M | 35.42M | 15.13M | 461.74M |
| P/E (TTM) | — | — | 0.7 | 0.4 | — | — |
| Forward P/E | -1.9 | -17.8 | -1.1 | — | -0.4 | 5.9 |
| Price/book | -25.1 | 3.8 | 0.4 | 3.3 | 0.2 | -1.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −70.86% | −30.70% | −21.77% | −39.34% | −58.18% | −56.78% |
| Today | −5.84% | −3.00% | +1.55% | +1.99% | −3.87% | −1.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PTHS news ›Latham & Watkins Advises Pelthos Therapeutics in Combination With Castle Creek Biosciences
Legal Desire Latham & Watkins Advises Pelthos Therapeutics in Combination With Castle Creek Biosciences Pelthos Therapeutics Inc. (NYSE American: PTHS), a commercial-stage biopharmaceutical company, and Castl
More from 1 other outlet
Pelthos and Castle Creek plan merger to target skin diseases
The agreement provides for up to $300m in milestone payments, including $50m tied to specified Phase III clinical endpoints. Pelthos Therapeutics has agreed to merge with Castle Creek Biosciences to form a new biotechnology company that…
Pelthos Therapeutics Announces Merger Agreement with Castle Creek Biosciences Featuring Two-Step Structure and Contingent Consideration
Is Crown Castle (NYSE:CCI) Poised for More Upside After Its Rally? Can Loews (NYSE:L) Justify Its Premium Valuation? Why Is OFG Bancorp (NYSE:OFG) Attracting Fresh Attention? Can Boeing (NYSE:BA) Recover After Its Latest Setbacks? On…
Pelthos to Merge With Castle Creek, Issuing 5.2 Million Shares Plus Up to $300 Million in Milestones
Agreement 1: Pelthos to Merge With Castle Creek, Issuing 5.2 Million Shares Plus Up to $300 Million in Milestones Agreement 2: Pelthos Lines Up Up to $80 Million in PIPE Financing for Castle Creek Merger Agreement 3: Pelthos Amends Horizon…
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
--Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, and Castle Creek Biosciences, Inc., a late-stage company developing redosable gene therapies,…
Pelthos Therapeutics stock sinks after Castle Creek merger deal
Pelthos shares sank 35% after its Castle Creek merger deal. - Pelthos Therapeutics (PTHS) shares fell ~35% to $10.79 on Friday after the company agreed to merge with Castle Creek Biosciences (CCBS), expanding its portfolio into cell and…
Pelthos To Merge With Castle Creek, Expanding Cell And Gene Therapy Pipeline
Pelthos Therapeutics, Inc. (PTHS) announced a definitive agreement to merge with Castle Creek Biosciences, creating a biotechnology company focused on developing treatments for serious skin diseases. Following the transaction, the combined…
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives Pelthos gains enhanced commercial coverage through a regional commercial health plan representing approximately 3…
Pelagos Insurance Capital Schedules Third Quarter 2026 Financial Results Conference Call
Pelagos Insurance Capital (NYSE: PLGO) expects to release third-quarter 2026 financial results on November 11, 2026, after financial markets close. Dan Burrows, Group Chief Executive Officer, Allan Decleir, Group Chief Financial Officer,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com2
- stocktitan.net2
- kalkinemedia.com1
- legaldesire.com1
- pharmaceutical-technology.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.